885588-03-4

Basic information

• Product Name: 3-(2-fluoro-4-iodophenylaMino)isonicotinic acid
• Synonyms: 3-(2-fluoro-4-iodophenylaMino)isonicotinic acid
• CAS NO: 885588-03-4
• Molecular Formula: C₁₂H₈FIN₂O₂
• Molecular Weight: 358.1069932
• Mol File: 885588-03-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 484.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.909±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.39±0.36(Predicted)
• CAS DataBase Reference: 3-(2-fluoro-4-iodophenylaMino)isonicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-fluoro-4-iodophenylaMino)isonicotinic acid(885588-03-4)
• EPA Substance Registry System: 3-(2-fluoro-4-iodophenylaMino)isonicotinic acid(885588-03-4)

Safety Data

• Hazardous Substances Data: 885588-03-4(Hazardous Substances Data)

Usage

General Description

3-(2-fluoro-4-iodophenylamino)isonicotinic acid is a chemical compound that belongs to the group of isonicotinic acids. It contains a fluorine and iodine atom in its structure, as well as a phenylamino group. 3-(2-fluoro-4-iodophenylaMino)isonicotinic acid is commonly used in medicinal and pharmaceutical research due to its potential biological and pharmacological activities. It has been studied for its potential applications in the development of new drugs for various medical conditions. Additionally, the unique chemical structure of 3-(2-fluoro-4-iodophenylamino)isonicotinic acid makes it a valuable tool for understanding the structure-activity relationships in drug design and development.

Upstream product

• 29632-74-4 2-fluro-4-iodoaniline 
• 393-53-3 3-fluoroisonicotinic acid 
• 402-65-3 2-fluoropyridine-4-carboxylic acid 

Downstream Products

• 1207201-30-6 N-[(3aS,4R,7aR)-2,2-dimethylhexahydro-1,3-benzodioxol-4-yl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR MEK INHIBITOR COMBINATION THERAPY IN THE TREATMENT OF CANCER

Combined administration of a hypoxia-activated prodrug, such as TH 302, and a MEK kinase inhibitor, such as pimasertib, are efficacious in the treatment of cancer including pancreatic cancer.

NOVEL HETEROARYL-SUBSTITUTED ARYLAMINOPYRIDINE DERIVATIVES AS MEK INHIBITORS

The invention provides novel heteroaryl-substituted arylaminopyridine derivative MEK inhibitors of Formula (Ia) Formula (Ia) Such compounds are MEK inhibitors that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation. Also disclosed is the treatment of a hyperproliferative disease in mammals, and pharmaceutical compositions containing such compounds